Dexcom (DXCM) Wells Fargo 21st Annual Healthcare Conference summary
Event summary combining transcript, slides, and related documents.
Wells Fargo 21st Annual Healthcare Conference summary
9 Sep, 2026CONNECT study and type 2 non-insulin opportunity
CONNECT trial results were strong and are expected to be published in a major journal soon, with additional follow-up studies ongoing and more data to be released over time.
Two CMS submissions are under review: one for all type 2 patients (mirroring commercial coverage) and another for those on glucose-lowering medication; CMS decision expected by mid-2027.
No discussions with CMS have included A1C thresholds or step therapy; focus remains on broad access and prevention.
Anticipated CMS coverage would significantly increase market coverage, potentially accelerating growth above the current 10%+ rate.
Achieving critical mass in coverage (around 70%) is expected to drive higher physician adoption and utilization.
Market trends, growth, and product performance
Patient base growth remains strong, with high-teens global growth expected this year, and new patient scripts growing at a similar rate to last year.
Recent commercial wins and expanded PBM coverage are improving access and driving recurring revenue.
The 15-Day product is performing well, with a goal to have about 50% of U.S. G-Series users transitioned by year-end; G6 production has been phased out.
No significant patient loss observed during the G6 to G7 transition; most users are moving smoothly to new products.
New patient starts hit record levels in Q1 and Q2 globally, with strong U.S. momentum and OUS performance influenced by tender timing.
Product innovation and pipeline
Smart Basal and "So What?" features are being developed to enhance patient engagement and outcomes, with AI coaching and integration of health data in Stelo and G-Series apps.
Stelo serves as a feeder to commercial coverage and is evolving with more consumer-centric features; $100 million in first 12 months despite limited initial features.
G8 is targeted for launch at the end of 2027 or early 2028, with design and software development progressing; potassium and ketones are prioritized as next analytes.
Hospital CGM is on track for a late 2027 launch, with regulatory pathway clarified and significant long-term opportunity anticipated.
Latest events from Dexcom
- Revenue growth and margin gains were offset by lower earnings and a major Verily charge.DXCM
Q4 2021 - Revenue grew 19% as G7 clearance and expanded CGM access strengthened growth prospects.DXCM
Q4 2022 - Revenue climbed 43% as profitability arrived and G6 capacity doubled.DXCM
Q4 2019 - 31% revenue growth and 66% gross margin, with earnings lifted by a major tax benefit.DXCM
Q4 2020 - G6-led revenue topped $1B as launch investment and the Verily charge widened losses.DXCM
Q4 2018 - Q3 revenue and margins grew, lifting FY2026 guidance and supporting a new $1B buyback.DXCM
Q3 2026 - Q4 revenue grew 26% organically as FDA submissions and G7 integrations advanced.DXCM
Q4 2023 - Q2 2026 revenue rose 13%, net income 39%, margins and guidance up, $600M shares repurchased.DXCM
Q2 2026 - Q3 2024 saw 2–3% revenue growth, strong international gains, and a $750M share repurchase.DXCM
Q3 2024